Topical Tranexamic Acid-mediated with Non-insulated Microneedling Radiofrequency for the Treatment of Melasma.

IF 1.8 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Israel Medical Association Journal Pub Date : 2025-06-01

Lehavit Akerman, Baruch Kaplan, Daniel Mimouni, Adi Nosrati, Efrat Solomon-Cohen

{"title":"Topical Tranexamic Acid-mediated with Non-insulated Microneedling Radiofrequency for the Treatment of Melasma.","authors":"Lehavit Akerman, Baruch Kaplan, Daniel Mimouni, Adi Nosrati, Efrat Solomon-Cohen","doi":"","DOIUrl":null,"url":null,"abstract":"Background: Radiofrequency-skin interaction is considered self-limited for treating acquired pigmentation such as melasma. Alternatively, skin perforation with microneedling radiofrequency (MNRF) may increase skin bioavailability for depigmenting-mediated ingredients or drugs for the treatment of melasma.Objectives: To examine the clinical feasibility of topical tranexamic acid (TA) mediated with MNRF-assisted transepidermal delivery in patients with mixed melasma.Methods: The study protocol included 14 women with centrofacial or malar pattern of distribution of melasma (skin types II-VI; age 35-48 years). Patients underwent four treatments at 3-week intervals between treatments. Treatment protocol included non-insulated MNFR (Intensif, EndyMed Ltd, Caesarea, Israel) followed by TA (hexakapron 4%) solution application. The improvement was evaluated based on clinical photographs (Quantificare, Biot, France) and modified Melasma Area and Severity Index (mMASI) scores. Baseline Photographs were analyzed 3 months after the last treatment.Results: In 13 patients (93%), mMASI scores were significantly lower after 3 months (mean 3.6) than at baseline (5.22). In one patient, mMASI was higher at 3 months compared to baseline. Overall, mMASI improved by 31% (P < 0.01). Physician and patient satisfaction was high. Minimal adverse reactions were recorded.Conclusions: MNRF-assisted transepidermal delivery with topical TA is a safe and effective modality for the treatment of melasma.","PeriodicalId":50268,"journal":{"name":"Israel Medical Association Journal","volume":"27 6","pages":"358-362"},"PeriodicalIF":1.8000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Israel Medical Association Journal","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Radiofrequency-skin interaction is considered self-limited for treating acquired pigmentation such as melasma. Alternatively, skin perforation with microneedling radiofrequency (MNRF) may increase skin bioavailability for depigmenting-mediated ingredients or drugs for the treatment of melasma.

Objectives: To examine the clinical feasibility of topical tranexamic acid (TA) mediated with MNRF-assisted transepidermal delivery in patients with mixed melasma.

Methods: The study protocol included 14 women with centrofacial or malar pattern of distribution of melasma (skin types II-VI; age 35-48 years). Patients underwent four treatments at 3-week intervals between treatments. Treatment protocol included non-insulated MNFR (Intensif, EndyMed Ltd, Caesarea, Israel) followed by TA (hexakapron 4%) solution application. The improvement was evaluated based on clinical photographs (Quantificare, Biot, France) and modified Melasma Area and Severity Index (mMASI) scores. Baseline Photographs were analyzed 3 months after the last treatment.

Results: In 13 patients (93%), mMASI scores were significantly lower after 3 months (mean 3.6) than at baseline (5.22). In one patient, mMASI was higher at 3 months compared to baseline. Overall, mMASI improved by 31% (P < 0.01). Physician and patient satisfaction was high. Minimal adverse reactions were recorded.

Conclusions: MNRF-assisted transepidermal delivery with topical TA is a safe and effective modality for the treatment of melasma.

本刊更多论文

局部氨甲环酸介导非绝缘微针射频治疗黄褐斑。

背景：射频-皮肤相互作用治疗获得性色素沉着（如黄褐斑）被认为是有局限性的。另外，用微针射频（MNRF）穿孔皮肤可以增加皮肤对脱色介导成分或治疗黄褐斑药物的生物利用度。目的：探讨外用氨甲环酸（TA）介导mrf辅助经皮给药治疗混合性黄褐斑的临床可行性。方法：研究方案纳入14例黄褐斑分布在中央面型或颧型的女性(皮肤类型II-VI；年龄35-48岁)。患者接受四次治疗，每次治疗间隔3周。治疗方案包括非绝缘MNFR (Intensif, EndyMed Ltd, Caesarea, Israel)，然后应用TA （hexakapron 4%）溶液。根据临床照片（Quantificare, Biot, France）和改进的黄褐斑面积和严重程度指数（mMASI）评分来评估改善情况。最后一次治疗后3个月分析基线照片。结果：在13例（93%）患者中，3个月后mMASI评分（平均3.6）明显低于基线（5.22）。在1例患者中，mMASI在3个月时高于基线。总体而言，mMASI改善了31% （P < 0.01）。医生和病人的满意度都很高。记录的不良反应最小。结论：mnrf辅助经皮给药外用TA是治疗黄褐斑的一种安全有效的方式。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Israel Medical Association Journal 医学-医学：内科

CiteScore

2.20

自引率

12.50%

发文量

审稿时长

3-8 weeks

期刊介绍： The Israel Medical Association Journal (IMAJ), representing medical sciences and medicine in Israel, is published in English by the Israel Medical Association. The Israel Medical Association Journal (IMAJ) was initiated in 1999.